OMB # 0925-0648

Expiration date: 06/30/2024

Public reporting burden for this collection of information is estimated to average 60 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.  Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch; 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

**NINDS Clinical Trial Networks Discussion Groups: Facilitator Script**

Thanks for participating in this discussion group to further elaborate on your experiences with the NeuroNEXT/StrokeNet network. We value your input collected through this discussion group in further assessing the networks’ delivery of services. The discussion group results will be used to inform improvements to implement in future renewals of the networks.

Please note that we plan to record these sessions for internal, notetaking purposes only. Participant statements during the online Zoom session will be recorded using the Zoom recording feature. Your responses will not be identified with you personally or with your organization; survey and discussion group results will only be in aggregate or de-identified form.

We will start recording.

Questions

1. Thinking about your survey responses regarding capacity/scale of NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions? In terms of number of trials, are there too many or too few sites?
2. Thinking about your survey responses regarding the scope of studies within NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions? Do you think it should be broader or narrower?
3. Thinking about your survey responses regarding the leadership and structure of NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions? Would you change it or not change it?
4. Thinking about your survey responses regarding the infrastructure of NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions? Would you change it or not change it?
5. Thinking about your survey responses regarding the quality and efficiency of NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions? Would you say that the quality and efficiency are high?
6. Thinking about your survey responses regarding the processes within NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions? Would you make any changes to existing processes or not change them at all?
7. Thinking about your survey responses regarding the trial pipeline within NeuroNEXT/StrokeNET, could you tell me more about the strengths/weaknesses/what you would change?”
8. Thinking about your survey responses regarding the site selection of NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions?
9. Thinking about your survey responses regarding the contracting of the NIH StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions?
10. Thinking about your survey responses regarding the start-up of NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions?
11. Thinking about your survey responses regarding the enrollment and retention of NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions?
12. Thinking about your survey responses regarding research and patient community engagement of NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions? Would you make any changes to how we do research and patient community engagement?
13. Thinking about your survey responses regarding training/researcher pipeline development within NeuroNEXT/StrokeNET, is there anything else you would like to add about what’s going well, what’s not going well, and your suggestions? Would you make any changes to how we do training?

Thank you for your time and thoughtfulness today. Please feel free to contact us if you think of any questions or additional comments. We have now ended the recording.